NCT05112835 - Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

September 8, 2022

Study Completion Date

September 8, 2022

Conditions

Neovascular Age-related Macular Degeneration

Interventions

OTHER

brolucizumab

There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study

Trial Locations (17)

PE3 9GZ

Novartis Investigative Site, Peterborough

LL22 8DP

Novartis Investigative Site, Abergele

BB2 3HH

Novartis Investigative Site, Blackburn

UB8 3NN

Novartis Investigative Site, Uxbridge

GU16 7UJ

Novartis Investigative Site, Frimley

BD9 6RJ

Novartis Investigative Site, Bradford

S75 2EP

Novartis Investigative Site, Barnsley

MK429DJ

Novartis Investigative Site, Bedford

CV2 2DX

Novartis Investigative Site, Coventry

G11 6NT

Novartis Investigative Site, Glasgow

HU3 2JZ

Novartis Investigative Site, Hull

EC1V 2PD

Novartis Investigative Site, London

NW10 7NS

Novartis Investigative Site, London

SK10 3BL

Novartis Investigative Site, Macclesfield

OX3 9DU

Novartis Investigative Site, Oxford

SR2 9HP

Novartis Investigative Site, Sunderland

CV34 5BW

Novartis Investigative Site, Warwick